Adding ganetespib to docetaxel in salvage therapy prolongs OS compared to docetaxel alone among patients diagnosed with advanced adenocarcinoma lung cancer, research presented at ASCO 2013 has found.
Low-dose weekly paclitaxel and standard every-other-week paclitaxel dosing offer equivalent postsurgical PFS rates among women with higher-risk early-stage breast cancer, according to research presented at ASCO 2013.
Simple vinegar-based visual inspection screenings by primary paramedical health workers reduced cervical cancer mortality by 31% over 15 years, research presented at ASCO 2013 has found.
Single-agent paclitaxel did not show equivalence to doxorubicin and cyclophosphamide as adjuvant therapy for breast cancer in women with zero to three axillary nodes, found data presented at ASCO 2013.
Among patients with newly-diagnosed glioblastoma, adding bevacizumab to standard first-line chemoradiotherapy does not improve survival, found data presented at ASCO 2013.
Axillary radiotherapy offers 5-year survival rates comparable to surgical dissection of the axillary lymph nodes, and a lower risk of lymphedema, according to research presented at ASCO 2013.
Bevacizumab extended survival in women with relapsed/advanced cervical cancer, the first time a targeted agent has significantly improved OS in gynecologic cancer, according to data presented at ASCO 2013.
Sorafenib represents a potential new treatment option for patients with locally advanced or metastatic RAI-refractory differentiated thyroid cancer, according to research presented at ASCO 2013.
Older African-American women with breast cancer are nearly 1.5 times more likely to have poor physical performance compared with non-Hispanic whites, found research presented at ASCO 2013.
Postsurgical surveillance alone allows patients with early-stage seminoma to forego unnecessary additional therapy without reducing cancer-specific survival, found data presented at ASCO 2013.
Please login or register first to view this content.
